Editorials
Why do cancer drugs get such an easy ride?
BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h2068 (Published 23 April 2015) Cite this as: BMJ 2015;350:h2068
Related articles
- Research Published: 23 September 2015; BMJ 351 doi:10.1136/bmj.h4633
- Analysis Published: 23 October 2015; BMJ 351 doi:10.1136/bmj.h5542
- Research Published: 18 September 2019; BMJ 366 doi:10.1136/bmj.l5221
See more
- Long term investment could avert 20 000 cancer deaths a year by 2040, says charityBMJ November 28, 2023, 383 p2809; DOI: https://doi.org/10.1136/bmj.p2809
- Working in the sun causes one in three non-melanoma skin cancer deaths, WHO warnsBMJ November 08, 2023, 383 p2621; DOI: https://doi.org/10.1136/bmj.p2621
- Anastrozole: Repurposed drug could prevent thousands of breast cancer casesBMJ November 07, 2023, 383 p2608; DOI: https://doi.org/10.1136/bmj.p2608
- Clinicians raise concerns over pilot of blood test for multiple cancersBMJ October 02, 2023, 383 p2268; DOI: https://doi.org/10.1136/bmj.p2268
- Ovarian cancer: NICE recommends expanding availability of genetic testingBMJ September 15, 2023, 382 p2111; DOI: https://doi.org/10.1136/bmj.p2111
Cited by...
- Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis
- Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?
- Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014
- Why the drug development pipeline is not delivering better medicines
- The FDA's new clothes
- Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study